RESUMO
Alzheimer disease is the most common type of dementia. Two classes of cognition-enhancing drugs are approved to treat the symptoms, and both have provided modest benefit in clinical trials. Psychotropic drugs are sometimes used off-label to treat behavioral symptoms of Alzheimer disease. All these medications should be continuously evaluated for clinical efficacy and, when appropriate, discontinued if the primary benefit--preservation of cognitive and functional status and a reduction in behaviors associated with dementia--is no longer being achieved.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Psicotrópicos/uso terapêutico , Doença de Alzheimer/complicações , Sintomas Comportamentais/tratamento farmacológico , Sintomas Comportamentais/psicologia , Transtornos Cognitivos/tratamento farmacológico , Transtornos Cognitivos/psicologia , Humanos , Resultado do Tratamento , Suspensão de TratamentoRESUMO
Dementia is commonly encountered in the elderly, with prevalence increasing with age. Although Alzheimer disease is the most recognized form of dementia, other types have distinct clinical features and are often overlooked. Proper identification aids patients, caregivers, and physicians in planning and management.
Assuntos
Encefalopatias/diagnóstico , Demência/diagnóstico , Envelhecimento/fisiologia , Encéfalo/patologia , Demência/fisiopatologia , Diagnóstico Diferencial , Diagnóstico por Imagem , Humanos , Doenças Neurodegenerativas/diagnósticoRESUMO
Primary progressive aphasia (PPA) is a distinct clinical entity in which the patient develops language deficits while other cognitive domains remain relatively preserved until late in the course of the illness. The diagnosis can be relatively clear through an appropriate diagnostic approach based on the history and physical examination. There is no cure, but speech therapy is beneficial in this illness.
